157 related articles for article (PubMed ID: 31095199)
21. Ertapenem resistance in 2 tertiary-care hospitals: Microbiology, epidemiology, and risk factors.
Maldonado N; Castro B; Berrio I; Manjarrés M; Robledo C; Robledo J
Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):511-515. PubMed ID: 26778651
[TBL] [Abstract][Full Text] [Related]
22. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.
Gutiérrez-Gutiérrez B; Bonomo RA; Carmeli Y; Paterson DL; Almirante B; Martínez-Martínez L; Oliver A; Calbo E; Peña C; Akova M; Pitout J; Origüen J; Pintado V; García-Vázquez E; Gasch O; Hamprecht A; Prim N; Tumbarello M; Bou G; Viale P; Tacconelli E; Almela M; Pérez F; Giamarellou H; Cisneros JM; Schwaber MJ; Venditti M; Lowman W; Bermejo J; Hsueh PR; Mora-Rillo M; Gracia-Ahulfinger I; Pascual A; Rodríguez-Baño J;
J Antimicrob Chemother; 2016 Jun; 71(6):1672-80. PubMed ID: 26907184
[TBL] [Abstract][Full Text] [Related]
23. Perioperative prophylaxis with ertapenem reduced infections caused by extended-spectrum betalactamase-producting Enterobacteriaceae after kidney transplantation.
Sanclemente G; Bodro M; Cervera C; Linares L; Cofán F; Marco F; Bosch J; Oppenheimer F; Dieckmann F; Moreno A
BMC Nephrol; 2019 Jul; 20(1):274. PubMed ID: 31331289
[TBL] [Abstract][Full Text] [Related]
24. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?
Eachempati SR; Hydo LJ; Shou J; Barie PS
J Trauma; 2009 May; 66(5):1343-8. PubMed ID: 19430237
[TBL] [Abstract][Full Text] [Related]
25. Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?
Barbier F; Pommier C; Essaied W; Garrouste-Orgeas M; Schwebel C; Ruckly S; Dumenil AS; Lemiale V; Mourvillier B; Clec'h C; Darmon M; Laurent V; Marcotte G; Lucet JC; Souweine B; Zahar JR; Timsit JF;
J Antimicrob Chemother; 2016 Apr; 71(4):1088-97. PubMed ID: 26755492
[TBL] [Abstract][Full Text] [Related]
26. Factors influencing the implementation of antibiotic de-escalation and impact of this strategy in critically ill patients.
Gonzalez L; Cravoisy A; Barraud D; Conrad M; Nace L; Lemarié J; Bollaert PE; Gibot S
Crit Care; 2013 Jul; 17(4):R140. PubMed ID: 23849321
[TBL] [Abstract][Full Text] [Related]
27. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.
Dalgic N; Sancar M; Bayraktar B; Dincer E; Pelit S
Scand J Infect Dis; 2011 May; 43(5):339-43. PubMed ID: 21271945
[TBL] [Abstract][Full Text] [Related]
28. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial.
Leone M; Bechis C; Baumstarck K; Lefrant JY; Albanèse J; Jaber S; Lepape A; Constantin JM; Papazian L; Bruder N; Allaouchiche B; Bézulier K; Antonini F; Textoris J; Martin C;
Intensive Care Med; 2014 Oct; 40(10):1399-408. PubMed ID: 25091790
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial treatment and outcomes of critically ill patients with OXA-48like carbapenemase-producing Enterobacteriaceae infections.
Lowman W; Schleicher G
Diagn Microbiol Infect Dis; 2015 Feb; 81(2):138-40. PubMed ID: 25497419
[TBL] [Abstract][Full Text] [Related]
30. Impact of antimicrobial strategies on clinical outcomes of adults with septic shock and community-onset Enterobacteriaceae bacteremia: de-escalation is beneficial.
Lee CC; Lee NY; Chen PL; Hong MY; Chan TY; Chi CH; Ko WC
Diagn Microbiol Infect Dis; 2015 Jun; 82(2):158-64. PubMed ID: 25796557
[TBL] [Abstract][Full Text] [Related]
31. Effect of Broad-Spectrum Antibiotic De-escalation on Critically Ill Patient Outcomes: A Retrospective Cohort Study.
Aldardeer N; Qushmaq I; AlShehail B; Ismail N; AlHameed A; Damfu N; Al Musawa M; Nadhreen R; Kalkatawi B; Saber B; Nasser M; Ramdan A; Thabit A; Aldhaeefi M; Al Shukairi A
J Epidemiol Glob Health; 2023 Sep; 13(3):444-452. PubMed ID: 37296351
[TBL] [Abstract][Full Text] [Related]
32. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
Behera B; Mathur P; Das A; Kapil A
Singapore Med J; 2009 Jun; 50(6):628-32. PubMed ID: 19551319
[TBL] [Abstract][Full Text] [Related]
33. Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae.
Blanchette LM; Kuti JL; Nicolau DP; Nailor MD
Scand J Infect Dis; 2014 Nov; 46(11):803-8. PubMed ID: 25262922
[TBL] [Abstract][Full Text] [Related]
34. Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study.
Zusman O; Farbman L; Tredler Z; Daitch V; Lador A; Leibovici L; Paul M
Clin Microbiol Infect; 2015 Jan; 21(1):54-8. PubMed ID: 25636928
[TBL] [Abstract][Full Text] [Related]
35. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics.
Alhambra A; Cuadros JA; Cacho J; Gómez-Garcés JL; Alós JI
J Antimicrob Chemother; 2004 Jun; 53(6):1090-4. PubMed ID: 15117925
[TBL] [Abstract][Full Text] [Related]
36. Resistance Rates of Intra-Abdominal Isolates from Intensive Care Units and Non-Intensive Care Units in the United States: The Study for Monitoring Antimicrobial Resistance Trends 2010-2012.
Hackel MA; Badal RE; Bouchillon SK; Biedenbach DJ; Hoban DJ
Surg Infect (Larchmt); 2015 Jun; 16(3):298-304. PubMed ID: 25894976
[TBL] [Abstract][Full Text] [Related]
37. Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit.
Yakovlev SV; Stratchounski LS; Woods GL; Adeyi B; McCarroll KA; Ginanni JA; Friedland IR; Wood CA; DiNubile MJ
Eur J Clin Microbiol Infect Dis; 2006 Oct; 25(10):633-41. PubMed ID: 17024505
[TBL] [Abstract][Full Text] [Related]
38. Impact of antibiotic de-escalation on hospitalized patients with urinary tract infections: A retrospective cohort single center study.
Alshareef H; Alfahad W; Albaadani A; Alyazid H; Talib RB
J Infect Public Health; 2020 Jul; 13(7):985-990. PubMed ID: 32276874
[TBL] [Abstract][Full Text] [Related]
39. De-escalation of antimicrobials in the treatment of bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patients.
Shime N; Satake S; Fujita N
Infection; 2011 Aug; 39(4):319-25. PubMed ID: 21509424
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes of carbapenem de-escalation regardless of microbiological results: A propensity score analysis.
Sadyrbaeva-Dolgova S; Aznarte-Padial P; Pasquau-Liaño J; Expósito-Ruiz M; Calleja Hernández MÁ; Hidalgo-Tenorio C
Int J Infect Dis; 2019 Aug; 85():80-87. PubMed ID: 31075508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
